Back to Annual Meeting Page		American Public Health Association 133rd Annual Meeting & Exposition December 10-14, 2005 Philadelphia, PA

Abstract #107248

J. Aaron Johnson, PhD, Institute for Behavioral Research, University of Georgia - Athens, 100 Barrow Hall, Athens, GA 30602, 706.542.6054, ajohns@uga.edu

Though there is strong support at the state and federal level to increase the use of evidence-based practices (EBPs) within addiction treatment programs, there is relatively little data on the extent to which individual EBPs have already been adopted. Likewise, the rate of adoption is virtually unknown. Buprenorphine, for example, was approved by the FDA in October 2003, but there is little information on the percentage of treatment programs that have adopted Buprenorphine or the rate at which its use is spreading across the addiction treatment system. The NIDA-funded National Treatment Center Study (NTCS) is able to provide this type of information on Buprenorphine as well as a number of other pharmacological and psychosocial EBPs. The NTCS includes nationally representative longitudinal data from 800 addiction treatment programs including government-owned as well as private for profit and private not for profit programs. Data collection on the use of EBPs began in 2000 and has continued to be collected from participating programs at 6-month intervals. This paper will examine five years of data on the use of both pharmacological and psychosocial EBPs. The most current rates of use for Buprenorphine, Naltrexone, Motivational Enhancement Therapy and other EBPs will be reported and longitudinal data will be examined to develop trend lines estimating adoption rates. Likewise, systematic differences between the public and private sectors will be examined as previous research has found significant public/private differences in the patterns of EBP adoption.

Learning Objectives: